Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group

Giacchetti, Sylvie; Bjarnason, Georg A.; Garufi, Carlo; Genet, Dominique; Iacobelli, Stéfano; Tampellini, Marco; Smaaland, Rune; Focan, C.; Coudert, Bruno; Humblet, Yves; Canon, Jean Luc; Adenis, Antoine; Re, Giovanni Lo; Carvalho, Carlos; Schueller, Johannes; Anciaux, Nicole; Lentz, M.A.; Baron, B.; Gorlia, Thierry; Lévi, Françis

doi:10.1200/jco.2006.06.1440

Cited by 201 publications

(191 citation statements)

References 34 publications

Supporting

Mentioning

182

Contrasting

Unclassified

Order By: Relevance

“…8,[36][37][38]43,44 It is interesting to note that the downstaging of unresectable liver metastases with modern neoadjuvant chemotherapy regimens has allowed potentially curative resection in up to 30% of patients across published series. 45 Furthermore, a recent analysis revealed that pathologic a complete response to chemotherapy is a major determinant of long-term survival and cure in patients with metastatic CRC.…”

Section: Discussionmentioning

confidence: 99%

“…36,37 Nevertheless, a recent, large, randomized trial using individual dose escalation revealed a survival advantage in men but not in women who received chronotherapy. 38 The combination of both HAI and chronomodulated delivery of multidrug regimens could further improve the therapeutic index of cytotoxic chemotherapy in patients who have liver metastases from CRC. The peak time of chronomodulated irinotecan at 5 AM corresponded to low proportion of S-phase cells in healthy tissues and to high Bcl-2 messenger RNA expression in oral mucosa and, presumably, in other healthy tissues.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer

Bouchahda

Adam

Giacchetti

et al. 2009

Cancer

Self Cite

View full text Add to dashboard Cite

Original carbohydrate‐based acrylamides bearing one azide group in C‐2 or C‐6 position namely, 2‐[(2‐deoxy‐2‐azido‐α‐D‐mannopyranosyloxy)ethanamido]‐ethyl acrylamide (II) and 2‐[(6‐deoxy‐6‐azido‐α‐D‐glucopyranosyloxy)ethanamido]‐ethyl acrylamide (III), and their azide‐free analogue, 2‐[(α‐D‐glucopyranosyloxy)ethanamido]‐ethyl acrylamide (I), have been designed. Whereas the reversible addition fragmentation chain transfer (RAFT) process ensured the preparation of well‐defined glycopolymers from I, the polymerization of monomers II and III proved to be challenging at temperatures compatible with a thermally initiated radical process, due to the presumed concomitant 1,3‐cycloaddition reactions between the azide and the acrylamide moieties. In contrast to III, for which no polymer could be obtained under any conditions, performing the RAFT polymerization of II at 30 °C clearly favored the radical polymerization and conferred a controlled character to the process, affording well‐defined azide‐functionalized glycopolymers and block copolymers. The presence of numerous azide moieties was finally exploited to introduce carbohydrates onto the glycopolymer backbone through copper catalyzed azide‐alkyne cycloaddition. © 2011 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem, 2011

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer

Bouchahda

Adam

Giacchetti

et al. 2009

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Patients in Cohort I received FL or FLO chronotherapy as first or second line chemotherapy Levi et al, 2007;Curé et al, 2002). Patients in Cohort II received first line chronoFLO or FOLFOX for metastatic disease (Innominato et al, 2009a;Giacchetti et al, 2006). Irinotecan-based chemotherapy was administered to 39.4% of the patients in Cohort III, and in none of the patients in either Cohort I or II.…”

Section: Patient Cohorts and Treatment Regimensmentioning

confidence: 99%

Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival

Lévi

Dugué

Innominato³

et al. 2014

Chronobiology International

Self Cite

101

View full text Add to dashboard Cite

Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival. Chronobiology International, 31 (8). pp. 891-900. Permanent WRAP URL:http://wrap.warwick.ac.uk/85076 Copyright and reuse:The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.Copies of full items can be used for personal research or study, educational, or not-for profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. A note on versions:The version presented here may differ from the published version or, version of record, if you wish to cite this item you are advised to consult the publisher's version. Please see the 'permanent WRAP URL' above for details on accessing the published version and note that access may require a subscription. Running titleRest-activity rhythm as a predictor of survival Key wordsBiomarkers, cancer, circadian clock, rest-activity rhythm, survival Interventional studies involving 24-h schedules of clock-targeted drugs, light intensity, exercise and/or meals are needed for testing the relevance of circadian synchronization for the survival of patients with disrupted rhythms.

show abstract

“…Of note, several prognostic factors have been found in previous clinical trials [2][3][4][5][6][7][8][9][10][11][12][13][14][15]. These were patient characteristics such as performance status (PS), age, sex, weight loss, biological variables such as white blood cell count (WBC), serum alkaline phosphatase (ALP) level, serum lactate dehydrogenase (LDH) level, serum carcino-embryonic antigen (CEA) level, or tumor characteristics like the number of metastatic sites or liver involvement (Table 1).…”

Section: Introductionmentioning

confidence: 99%

Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study

et al. 2011

View full text Add to dashboard Cite

received from Genentech, Bristol-Myers Squibb, and Pfizer; and ownership interest with Tetralogic Pharmaceuticals. Reviewer "A" discloses no financial relationships. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. On the basis of disclosed information, all conflicts of interest have been resolved. LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Describe prognostic factors in metastatic colorectal cancer. 2. Estimate prognostic score with a simple model using only PS and LDH as parameters.This article is available for continuing medical education credit at CME.TheOncologist.com. The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. CME CME Gastrointestinal CancerThe Oncologist 2011;16:1228 -1238 www.TheOncologist.com ABSTRACTBackground. The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer. Patients and Methods. Eight hundred three patients treated with FOLFOX or FOLFIRI in three prospective trials were randomly separated into learning (n ‫؍‬ 535) and validation (n ‫؍‬ 268) samples. Eleven baseline variables were evaluated in univariate and multivariate analysis as prognostic factors for overall survival, and a prognostic score was developed.Results. Independent prognostic factors identified in multivariate analysis for overall survival were performance status (PS) (p < .001), serum lactate dehydrogenase (LDH) (p < .001), and number of metastatic sites (p ‫؍‬ .005). A prognostic score based on these three vari-

show abstract

Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group

Cited by 201 publications

References 34 publications

Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer

Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer

Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival

Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study

Contact Info

Product

Resources

About